Log In
Print this Print this

GALNS Enzyme Replacement Therapy

  Manage Alerts
Collapse Summary General Information
Company Vivendy Therapeutics Ltd.
DescriptionRecombinant human fusion protein containing a peptide sequence of 4-15 amino acids attached at the N terminus of the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) enzyme
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis IVA (MPS IVA)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today